DOCSLIB.ORG

US Approves OTC Differin in First Retinoid Drug Switch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

OTC22-07-2016p1_OTC15/11/2005 p1&24 19/07/2016 12:57 Page 1 22 July 2016 COMPANY NEWS 2 US approves OTC Differin Moberg buys three brands 2 from Prestige J&J takes 19.9% stake 3 in Japan’s Ci:z Holdings in first retinoiddrugswitch WBA to enter South Korea 4 with Emart cne sufferers in the US will soon be able Taisho takes DHG stake 5 Ato buyGalderma’sadapalene-based to aid its expansion plans Differin Gel 0.1% without aprescription, Alibaba grabs Chinese pharmacy chain 6 after the Food and Drug Administration Japan’s Suntorypicks up 7 (FDA)approvedthe product for OTC sale. GSK’s drinks in Nigeria Differin is the first retinoid-based product Alphrema purchase grows 8 to be made available OTCfor the treatment of Urgo’s presence in Italy acne in the US, with adapalene the first new Pharmacy2U agrees merger 8 ingredient for treating acne to be switched in the country since the 1980s. The product has Differin Gel 0.1% is the first retinoid-based product to GENERAL NEWS 9 been approvedfor the OTCtreatment of acne be available OTC in the US vulgaris in people aged 12 years or older. vations to enhance skin health,”hesaid. German experts against 9 Miles Harrison, president and general man- Commenting on the switch, LesleyFurlong, switching metronidazole ager of Galderma, claimed that the switch would deputy director of the FDA’sOffice of New PRACopens safetyreview 10 be a“game-changer for consumers and the acne Drugs IV,said that millions of consumers, of modified paracetamol category”, butdid not give alaunch date for from adolescents to adults, would nowhave BAH wants EMA to move to Bonn 10 the OTCproduct. access to a“newsafe and effective OTCoption” German manufacturers 11 “Weare excited to deliverthis levelofeffi- for tackling their acne. anticipateconsolidation cacy without aprescription to consumers,”he Differin’ssafety and efficacyhad initially ICH welcomes WSMI as amember 11 added, “and to bring the first newactive in- been establishedthrough five clinical trials in CHPAand FDAdebate 12 gredient to the category for over30years.” people with mild to moderate acne, the FDA user-fee system Acne wasthe most common skin condition pointed out. To support its OTCswitch appli- in the US, Galderma pointed out, affecting up cation, Galderma had submitted post-market- MARKETING NEWS 13 to 60 million teens and adults annually. ing safety data accrued between 1996 –when Bayeradds TENS device 13 However, only athird of those affected the product wasapprovedasaprescription to Aleve range in the US sought the help of ahealthcare provider to product –and 2016, the agencyadded. Con- ASA bans Nurofen 14 tackle the problem, the companynoted, add- sumer studies, including alabel comprehension Joint &Back spot ing that 45% of adults were not satisfied with study,aself-selection study and an actual-use Remisens peps up Germans’ sexlives 14 theproducts theyused, with nearly half of them trial, as well as data from amaximum-use trial, Social data can 15 using three or more acne products. had also been submitted. back product claims There wasagrowing trend amongst con- Overall, results from the consumer studies Startengaging with consumersdigitally 16 sumers to self-treat, with manyturning to the had shown that consumers understood the in- Digital media promoteshealth literacy 17 skin-care aisle at their local drugstore, Gal- formation on the OTClabelling of the prod- derma said. Until now, however, there had only uct, the FDAsaid, could appropriately select Pharma FGP spends C5mn 18 on Neodolor television push been five active ingredients available OTCin whether the product wasright for them and the US, with twoofthose ingredients–ben- use the product correctly. Stada renames Hoggar Balance 18 zoyl peroxide and salicylic acid –accounting Furthermore, the maximum use trial –a FEATURES 20 for 99% of the market. study of absorption of the drug through acne- Philip Brown, Galderma’ssenior vice-pres- affected skin when applied daily overalarge Perrigo offers ‘total healthcare’ 20 ident for medical and regulatory affairs, said surface area –had demonstrated that absorp- in the UK the switch had been “years in the making”. tion waslimited, thus supporting safe OTCuse, “This landmark approvaldemonstrates our the FDApointed out. REGULARS ongoing commitment to individuals with der- The switch receivedfinal approvalafter Events – Our regular listing 19 matologic concerns such as acne,”headded. the FDA’sNonprescription Drugs Advisory People – Stada makes board 23 “Galderma will continue to partner with health- Committee (NDAC)voted unanimously in picks to counter activist investor care professionals and invest in prescription, April to recommend switching adapalene gel OTC, aesthetic and correctivemedical inno- ■ Continued on page 11 OTC22-07-2016p2-9_Layout 1 19/07/2016 12:57 Page 2 OTC COMPANY NEWS Mergers&Acquisitions Mobergbuys three brands from Prestige weden’sMobergPharma has expanded fur- Commenting on the rationale behind the Stherits presence in the US consumer health- deal, Peter Wolpert, Moberg’schief executive care market by acquiring three brands from Pres- officer,said the acquisition was“in line with tige Brands for US$40 million (C36 million). ourstrategy to add critical mass to our US op- The three brands –Fiber Choice, New-Skin erations, as well as aleading topical brand to and PediaCare –had generated sales of around our core dermatology franchise”. US$24.4 million in the year ended 31 March “The acquired brands,”continued Wolpert, 2016, Mobergsaid, and were “well-established” “will immediately contribute significantly to in the US OTCmarket. our sales and earnings and also to our long-term The New-Skin liquid bandage wasthe “main financial goal of delivering profitable growth profitabilitycontributor” in the acquired port- andanearnings before interest, tax, depreciation MobergPharma has snapped up three brands –including the New-Skin liquid bandage –fromPrestige Brands folio, the companypointed out, and was“well- and amortisation (EBITDA) margin of 25%.” aligned with Moberg’sstrategic focus on topi- “This transaction is an excellent use of the brands would enable Mobergtofocus further cal dermatology”. proceeds from the bond loan issue earlier this on its “strategic assets, and mergers and ac- “Wesee excellent opportunities to build on year and the funds releasedinthe recent di- quisitions activities”. thebrand equity of New-Skin,”commented Jeff vestment of non-core brands to Strides Phar- Moberg’sstrategic OTCbrands include the Vernimb, general manger of MobergPharma ma,”Wolpert added. Balmexdermatology range, Domeboro skin- North America. In February,Mobergissued abond valued at care line and the Kerasal Nail/Nalox/Emtrix “This is amarket-leading brand with exciting SEK300 million (C32.2 million),with the com- anti-fungal nail-carebrand. prospects for growth,”Vernimb insisted. “We panynoting that the proceeds would allowthe Meanwhile, Prestige said offloading New- will leverage our innovation engine to further firm to “increase its acquisitionactivities going Skin, Fiber Choice and PediaCare to Moberg strengthen the future value proposition of this forward”, expand the international distribution would enable the firm to “move closer to its brand, as well as Fiber Choice and PediaCare, of its products and “strengthen” the “brand plat- stated goal of having aportfolio consisting of to consumers and retailers.” forms” of its strategic brands in the US market 85% of its revenue from ‘invest for growth’ The PediaCare children’spain-relief brand (OTC bulletin,5February 2016, page 8). brands and 15% in ‘manage for cash’ brands”. had “strong equity amongst mums” thanks to its The following month, Mobergoffloaded Achieving this goal, Prestige claimed, would “highly-effective products”, Vernimb insisted, the Fergon, JointFlexand Vanquish brands to “help support long-term organic growth”. while the Fiber Choice range comprised a“com- India’sStrides for US$10 million (OTC bul- Prestige noted that it planned to use the pelling line-up of product options for daily letin,25March 2016, page 2). proceeds from the sale to “pay down debt and fibre supplementation”. Wolpert said at the time that selling the three accelerate de-leveraging”. OTC Distribution contract and IN BRIEF ■ ACHÉ LABORATÓRIOS –the Brazil- product rights on offer ... ian OTCand prescription medicines manu- facturer –has strengthened its position in its domestic market by snapping up Laborat- German companycompany is sellingsellinga food for special ório Químico Farmacêutico Tiaraju for an undisclosed sum. Through the deal, Aché gains medicalmedical purposespurposes for diabetes type IIII.. Tiaraju’srange of herbal medicines, nutra- ceuticals and nutricosmetics. Santo Ângelo- The product fulfils the criteria laid down in the European Union based Tiaraju’sportfolio comprises the Ad- Regulation 609/2013 that comes into effect on 20 July 2016. mire skin-care line, Biofibra herbal supple- On offer is a distribution contract exclusively for the German market ment and the MultiVita multivitamin. Aché reported sales up by 9.3% to BRL2.3 billion which will run until 2021, as well as the product rights. (C634 million) in 2015, thanks to newprod- As the product has been extensively analysed and clinically-proven, uct launches across its non-prescription and claims can be made on its packaging, as determined by a structure- prescription medicines businesses. The com- function or astructure-illness relation for the ingredients. pany’sOTC portfolio includes the Accuvit multivitamin, Dorilax analgesic
Recommended publications
  • All Together. Different. Svi Zajedno

    All Together. Different. Svi Zajedno

    Diversity & Inclusion Report 2018–19 All Together. Different. Svi zajedno. Različiti. • Všichni společně. • Každý jiný. • Eensgezind. Anders. • Tous ensem- ble, tous différents. • Einträchtig. Anders. • Tut- ti assieme, ma diversi. • Visi kartu. Skirtingi. • Alle sammen. Forskjellige • Todos juntos. TableDifer of Contents- Deepening Our Diversity and Inclusion entes. • Împreună. Diferiți • Hep birlikte. FaEmphasisrklı. ............................................... 1 • Svi zajedno. Različiti. • Všichni společněMessages. • from Our CEO, Global Chief Human Resources Officer and Our Global Každý jiný. • Eensgezind. Anders. • Tous enChief -Diversity Officer ........................2–3 Our D&I Impact Is Expansive semble, tous différents. • Einträchtig. Anderand Expandings. • ...................................... 4 WBA Strengthens Its D&I Strategy, Tutti assieme, ma diversi. • Visi kartu. SkirtiData Collectionngi. ............................... 6–13 Our Business Resource Groups Foster Inclusive Global Cultures ................ 14–21 All Together. Different. Împreună. Diferiți • Expanding Business Opportunities Todos juntos. Diferentes. • Hep birlikte. Farklby Attracting,ı. Nurturing Diverse Suppliers .......................... 22–25 • Svi zajedno. Različiti. • Všichni společně.WBA • Earns Wide Recognition for D&I Leadership ........................ 26–27 Každý jiný. • Eensgezind. Anders. • Tous ensemLooking Ahead ....................................- 29 ble, tous différents. • Einträchtig. Anders. • Tut- ti assieme, ma diversi. • Visi kartu.
  • Suppression of Prostate Tumor Cell Growth by Stromal Cell Prostaglandin D Synthase–Derived Products

    Suppression of Prostate Tumor Cell Growth by Stromal Cell Prostaglandin D Synthase–Derived Products

    Research Article Suppression of Prostate Tumor Cell Growth by Stromal Cell Prostaglandin D Synthase–Derived Products Jeri Kim,1 Peiying Yang,2 Milind Suraokar,3 Anita L. Sabichi,3 Norma D. Llansa,3 Gabriela Mendoza,3 Vemparalla Subbarayan,3 Christopher J. Logothetis,1 Robert A. Newman,2 Scott M. Lippman,3 and David G. Menter3 Departments of 1Genitourinary Medical Oncology, 2Experimental Therapeutics, and 3Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Abstract seminal fluid (10). Once PGD2 is made, it forms derivative Stromal-epithelial interactions and the bioactive molecules compounds, most of which can transactivate the peroxisome g g produced by these interactions maintain tissue homeostasis proliferator–activated receptor (PPAR ). One PGD2 derivative, 15-deoxy-D12,14-prostaglandin J (15-d-PGJ ), can slow the growth and influence carcinogenesis. Bioactive prostaglandins pro- 2 2 duced by prostaglandin synthases and secreted by the prostate and induce the partial differentiation of selected cancer cells (12). D12,14 into seminal plasma are thought to support reproduction, but Another PGD2 derivative, 15-deoxy- -PGD2 (15-d-PGD2), has g their endogenous effects on cancer formation remain unre- also been shown to stimulate PPAR transactivation in RAW 264.7 solved. No studies to date have examined prostaglandin cell macrophage cultures as effectively as 15-d-PGJ2 (13). L-PGDS enzyme production or prostaglandin metabolism in normal also binds tritiated testosterone and may play a role in androgen prostate stromal cells. Our results show that lipocalin-type transport (14). In castrated rats, testosterone proprionate induces prostaglandin D synthase (L-PGDS) and prostaglandin D L-PGDS synthesis in the epididymis (15).
  • Outpatient Acne Care Guideline

    Outpatient Acne Care Guideline

    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
  • Therapeutic Drug Class

    Therapeutic Drug Class

    BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 04/01/11 This is not an all-inclusive list of available covered drugs and includes only Version 2011.9 managed categories. Refer to cover page for complete list of rules governing this PDL. • Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. • Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) • Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. • PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. • The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
  • At the Heart of Health Corporate Social Responsibility Report

    At the Heart of Health Corporate Social Responsibility Report

    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
  • News: Interview with Ornella Barra on Forbes Monaco

    News: Interview with Ornella Barra on Forbes Monaco

    THE NEXT BILLION DOLLAR SAFARI BUSINESS BILLION- A CASE FOR MONACO’S EU DEAL DOLLAR STARTUPS TRUMP UNCONSTRAINED THE $6 BILLION WEATHER WARS “I’ve always had an entrepreneurial mindset and curious att itude. This empowered me to envision pharmacy’s full potential.” SPECIAL ENTREPRENEURIAL WOMEN Over the Counter with Ornella Barra HOW THE COMMUNITY PHARMACIST TURNED M 31766 5 F : €9 RD DRUGSTORE MOGUL IS 00030 BREAKING THE GLASS 9.50 CEILING. 3 783176 609006 Benelux: AUGUST 2019 MONACO FEMALE ENTREPRENEURS THE PROFILE 42 43 RANKED LAST YEAR AS ONE OF THE MOST POWERFUL WOMEN IN BUSINESS OUTSIDE THE U.S., PHARMACIST ORNELLA BARRA FOUNDED A WHOLESALE BUSINESS IN 1984 THAT TWO YEARS LATER BECAME ITALY’S LEADING DRUG DISTRIBUTOR WHEN IT MERGED WITH ALLEANZA SALUTE ITALIA, HEADED BY STEFANO PESSINA. THE COUPLE’S GREAT CHEMISTRY HAS ENDURED OVER 35 YEARS AND BARRA IS NOW CO-COO OF THE WORLD’S LARGEST DRUGSTORE CHAIN, WALGREENS BOOTS ALLIANCE. OTHESE BOOTS ARE MADE FOR WALGREENS BY CELINA LAFUENTE DE LAVOTHA PHOTOTGRAPH BY THIERRY BEAUVILAIN OUVRARD AUGUST 2 019 FORBES MONACO ambitious drive, she knew her career options would be arra stepped into her co-COO role in today and we are right in the middle of this evolution. limited. She instead studied Pharmacy at the University of June 2016 and oversees Global Brands, The nature of medicines is changing, as we see with Genoa, then managed a local pharmacy before acquiring B Pharmaceutical Wholesale, the Retail the growing importance of pharmacogenetics [the one in her hometown in 1979. “I always wanted to build Pharmacy International businesses outside study of the role of the genome in drug response].” something important for myself and others.
  • Leading by Example Stefano Pessina Won the 2013 Clarity Search Retail Leader of the Year Award

    Leading by Example Stefano Pessina Won the 2013 Clarity Search Retail Leader of the Year Award

    Sponsored by THE CLARITY SEARCH RETAIL LEADER OF THE YEAR Leading by example Stefano Pessina won the 2013 Clarity Search Retail Leader of the Year award. Tiffany Holland talks to the Alliance Boots executive chairman to find out why he’s ahead of the pack n first meeting, it’s easy Last year the self-made billionaire to guess that Stefano revealed that Alliance Boots would Pessina is an entrepre- be partnering with US drugstore Oneur. He wears the sort of chain Walgreens, which will even- sharp suits you’d expect of a billion- tually lead to a full merger. aire and his confident, composed It was one of the most remarkable air could calm any boardroom. business moves in years, as Alliance As the boss of Alliance Boots, Boots, which earned a trading profit one of the largest retailers in the UK of £1.2bn in the last financial year, and one of the biggest pharmaceuti- joined forces with Walgreens’ cal wholesalers in the world, he is empire of 8,000 stores. known for his serene demeanour – The US retailer generated an oper- something that was undoubtedly ating income of $3.5bn (£2.3bn) in useful last June when he brokered the same financial year. In June it the landmark retail deal of 2012. was revealed that Walgreens would But when Retail Week speaks to initially invest $6.7bn (£4.5bn) in him, the Italian businessman is in cash and stocks to acquire 45% high spirits, cracking jokes and equity in Alliance Boots, with a revelling in the recognition his view to merge within three years.
  • Lipocalin-Type Prostaglandin D Synthase Regulates Light-Induced Phase Advance of the Central Circadian Rhythm in Mice

    Lipocalin-Type Prostaglandin D Synthase Regulates Light-Induced Phase Advance of the Central Circadian Rhythm in Mice

    ARTICLE https://doi.org/10.1038/s42003-020-01281-w OPEN Lipocalin-type prostaglandin D synthase regulates light-induced phase advance of the central circadian rhythm in mice Chihiro Kawaguchi et al.# 1234567890():,; We previously showed that mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) exhibit attenuated light-induced phase shift. To explore the underlying mechan- isms, we performed gene expression analysis of laser capture microdissected suprachias- matic nuclei (SCNs) and found that lipocalin-type prostaglandin (PG) D synthase (L-PGDS) is involved in the impaired response to light stimulation in the late subjective night in PACAP- deficient mice. L-PGDS-deficient mice also showed impaired light-induced phase advance, but normal phase delay and nonvisual light responses. Then, we examined the receptors involved in the response and observed that mice deficient for type 2 PGD2 receptor DP2/ CRTH2 (chemoattractant receptor homologous molecule expressed on Th2 cells) show impaired light-induced phase advance. Concordant results were observed using the selective DP2/CRTH2 antagonist CAY10471. These results indicate that L-PGDS is involved in a mechanism of light-induced phase advance via DP2/CRTH2 signaling. #A list of authors and their affiliations appears at the end of the paper. COMMUNICATIONS BIOLOGY | (2020) 3:557 | https://doi.org/10.1038/s42003-020-01281-w | www.nature.com/commsbio 1 ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01281-w he mammalian circadian clock system comprises the genes (Fig. 1a). Of these 593 genes, we specifically analyzed genes endogenous master pacemaker located within the supra- that were upregulated (>1.7-fold change) or downregulated (>0.6- T −/− chiasmatic nucleus (SCN) in the hypothalamus and coor- fold change) by light stimulation in PACAP and wild-type mice.
  • Rosuvastatin and Atorvastatin Are Ligands of the Human Constitutive Androstane Receptor/Retinoid X Receptor a Complex S

    Rosuvastatin and Atorvastatin Are Ligands of the Human Constitutive Androstane Receptor/Retinoid X Receptor a Complex S

    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2017/05/23/dmd.117.075523.DC1 1521-009X/45/8/974–976$25.00 https://doi.org/10.1124/dmd.117.075523 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:974–976, August 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Short Communication Rosuvastatin and Atorvastatin Are Ligands of the Human Constitutive Androstane Receptor/Retinoid X Receptor a Complex s Received February 21, 2017; accepted May 17, 2017 ABSTRACT Statins are well known lipid lowering agents that inhibit the enzyme models of CAR/RXRa-LBD were constructed by ligand-based and – 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase. They also structure-based in silico modeling. Experiments and computational Downloaded from activate drug metabolism but their exact receptor-mediated action modeling show that atorvastatin and rosuvastatin bind to the human has not been proven so far. We tested whether atorvastatin and CAR/RXRa-LBD heterodimer, suggesting both can modulate the rosuvastatin are direct ligands of human constitutive androstane activity of CAR through direct interaction with the LBD of this receptor (CAR). We measured binding activities of atorvastatin and receptor. We confirm that atorvastatin and rosuvastatin are direct rosuvastatin to the human constitutive androstane receptor/retinoid ligands of CAR. The clinical consequences of CAR activation by X receptor a ligand-binding domain (CAR/RXRa-LBD) heterodimer statins are in their potential drug-drug interactions, and changes in dmd.aspetjournals.org with surface plasmon resonance (SPR). Additionally, three-dimensional glucose and energy metabolism.

  • Give Me More! the New Marketing Mantra in Hair Care

    AN ISSUE OF WOMEN’S WEAR DAILY THE BUSINESS OF BEAUTY HOLLYWOOD’S RED CARPET WHIZ KIDS INFOMERCIAL-MANIA DOLLAR STORES CASH IN GIVE ME MORE! THE NEW MARKETING MANTRA IN HAIR CARE %%3*;&29(5DLQGG 30 $QQSPWFEXJUIXBSOJOHT WWD BEAUTY INC 3 FEATURES 26 Small Screen Dreams The infomercial channel is booming as established players look to solidify their CONTENTS position amidst an onslaught of new entrants. 30 Maximum Volume Hair-care marketers are aiming to transform the way women approach hair-care regimens—and pump up sales to boot. 36 Penny Press As one of the fastest-growing channels in retail, the value-oriented dollar stores are now also the most competitive. 40 Red Carpet Whiz Kids Hollywood’s hottest young hair stylists and makeup artists. DEPARTMENTS CORNER OFFICE 8 The Laugh Master Under Aurelian Lis, Benefit’s humorous ethos has flourished, but the brand’s explosive growth in North America is no joke. 10 Black Book: Brooke Wall The super-chic founder of The Wall Group shares her favorite L.A. haunts. 11 My First Job: Jerrod Blandino Getting creative at Chuck E. Cheese. BEAUTY BULLETIN 14 Pop Rocks Spring’s bright color palette. 16 Launch Window Key products hitting stores now. 18 Singular Sensations Inspired looks from the European runways. CONSUMER CHRONICLES 20 Tinseltown’s Newest Beauty Destination Testing the waters at Hollywood’s swanky new Walgreens. 24 Shopper Stalker Who’s buying what—and why– on Manhattan’s Upper West Side. MISC 6 Pete Unplugged Pete Born, WWD’s executive editor of beauty, surveys the global indie beauty scene.
  • Retinoid-Induced Apoptosis in Normal and Neoplastic Tissues

    Retinoid-Induced Apoptosis in Normal and Neoplastic Tissues

    Cell Death and Differentiation (1998) 5, 11 ± 19 1998 Stockton Press All rights reserved 13509047/98 $12.00 Review Retinoid-induced apoptosis in normal and neoplastic tissues Laszlo Nagy1,3,4, Vilmos A. Thomazy1, Richard A. Heyman2 retinoic acid receptor (RAR), which belongs to the superfamily and Peter J.A. Davies1,3 of ligand-activated transcription factors (nuclear receptors) revolutionized our understanding as to how retinoids exert 1 Department of Pharmacology, University of Texas-Houston, Medical School, their pleiotropic effects (for reviews see Chambon (1996); Houston, Texas 77225 USA Mangelsdorf et al (1994)). Members of the nuclear receptor 2 Ligand Pharmaceuticals, San Diego, California, 92121 USA superfamily mediate the biological effects of many hormones, 3 Corresponding author: PJAD, tel: 713-500-7480; fax: 713-500-7455; vitamins and drugs (i.e. steroid hormones, thyroid hormones, e-mail: [email protected] 4 vitamin D, prostaglandin-J (PG-J ) and drugs that activate Present address for correspondence: The Salk Institute for Biological Studies, 2 2 Gene Expression Laboratory, La Jolla, California 92037; peroxisomal proliferation). There are two families of retinoid tel: (619) 453-4100 fax:(619) 455-1349; e-mail: [email protected] receptors, Retinoid X Receptors (RXRs) that bind 9-cis retinoic acid (9-cis RA) and Retinoic Acid Receptors (RARs) Received 18.8.97; revised 19.9.97; accepted 22.9.97 that bind both 9-cis RA and all-trans retinoic acid (ATRA) (for Edited by M. Piacentini reviews see Chambon 1996; Mangelsdorf et al, 1994)). Each of these receptor families includes at least three distinct genes, (RARa,b and g; RXRa,b and g) that through differential Abstract promoter usage and alternative splicing, give rise to a large number of distinct retinoid receptor proteins (for reviews see Vitamin A and its derivatives (collectively referred to as Chambon 1996; Mangelsdorf et al, 1994).
  • A Double-Blind Controlled Trial of Etretinate (Tigason) and Ibuprofen in Psoriatic Arthritis

    A Double-Blind Controlled Trial of Etretinate (Tigason) and Ibuprofen in Psoriatic Arthritis

    Ann Rheum Dis: first published as 10.1136/ard.44.3.189 on 1 March 1985. Downloaded from Annals of the Rheumatic Diseases, 1985; 44, 189-193 A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis R HOPKINS, H A BIRD, H JONES, J HILL, K E SURRALL, C ASTBURY, *A MILLER, AND V WRIGHT From the Clinical Pharmacology Unit, Royal Bath Hospital, Harrogate, and the General Infirmary at Leeds, and *Roche Products Limited, Welwyn Garden City, Hertfordshire SUMMARY Etretinate (Tigason) and ibuprofen have been compared in a double-blind controlled trial in psoriatic arthritis to see if we could confirm a specific action for this vitamin A derivative suggested from earlier uncontrolled studies. Eleven out of 20 patients completed 24 weeks of therapy with etretinate (up to 0-5 mg/kg/day) whereas only 1/20 patients completed 24 weeks of therapy with ibuprofen alone. Etretinate improved skin lesions, and this may have encouraged patients to persist with it. Improvement of statistical significance was seen for articular index in both groups. In addition significant improvement in ESR, haemoglobin, C-reactive protein, and histidine occurred in the etretinate group. The main side effects of etretinate (which may preclude its use at a higher dose in this condition) included cracked and dried lips and sore mouth. copyright. Etretinate (Tigason) is a vitamin A derivative. The provement in 99m technetium scans of the hands and parent vitamin is essential for growth, maintenance feet, and 'no progression of destructive change' on of visual function, and the regulation of prolifera- x-rays.5 Rosenthal et al.